Newsletter
donate now

Search Results for: Ibrutinib – Page 4

ASH 2022: Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL / SLL; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

March 16, 2023

The first interim analysis of the Phase 2 HOVON 158/Next Step Trial was conducted halfway through a 15-month course of treatment with ibrutinib and venetoclax. As compared to baseline, PET-CT scanning showed a decrease in metabolic activity in all but one patient. However, despite the decrease in metabolic activity and, in some cases, normal metabolic activity on PET-CT scans, several patients had persistently enlarged lymph nodes.

ASH 2022: Dr. Paolo Ghia on Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) who Received First-Line Treatment with Ibrutinib

March 16, 2023

Targeted therapies have greatly improved survival outcomes for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). For example, Ibrutinib is so effective at controlling CLL / SLL that the overall survival of patients treated with first-line ibrutinib is no different from that of the general population.

ASH 2022: Dr. John Allan on Outcomes for Chronic Lymphocytic Leukemia (CLL) Patients with Undetectable Measurable Residual Disease (MRD) After Treatment with Ibrutinib Plus Venetoclax

March 16, 2023

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who achieved undetectable measurable (or minimal) residual disease (uMRD) after fixed-duration ibrutinib + venetoclax treatment continue to have excellent outcomes four years after stopping initial therapy. The results of this study suggest that if patients achieve uMRD remission, it is safe to stop treatment.

ASH 2022: Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab, Ibrutinib, and Venetoclax in Untreated Patients with CLL with 17p Deletion/TP53 Mutation

February 23, 2023

Fixed duration combination therapy of obinutuzumab, ibrutinib, and venetoclax with treatment adjustment based on clinical response and results of measurable residual disease testing shows high efficacy and safety for the front-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL) patients with del (17p) or TP53 mutation offering exciting hope for what has been an unmet need for this group of patients with high-risk disease.

ASH 2022: Dr. Clare Sun Explains Her Research on Sudden Death Among a Small Number of Chronic Lymphocytic Leukemia (CLL) Patients Using Ibrutinib

January 24, 2023

Dr. Sun was interviewed by Dr. Brian Koffman, a physician, CLL patient, and executive vice president and chief medical officer of CLL Society, at the ASH 2022 meeting in New Orleans. In the interview, she elaborates on the research results and recommendations on how patients can avoid cardiac issues while taking ibrutinib or other Bruton’s tyrosine kinase (BTK) inhibitors.

ASH 2022: Dr. John Seymour on the Adverse Event Burden of Acalabrutinib vs. Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

January 24, 2023

In this interview, our own Dr. Brian Koffman interviewed Dr. John Seymour, Director of the Department of Hematology at Peter MacCallum Cancer Centre & Royal Melbourne Hospital in Melbourne, Australia. They discussed the latest updates to the safety data from the ELEVATE R/R study, which was the first clinical trial to compare acalabrutinib and ibrutinib head-to-head.

Didn't find what you where looking for?

Try our advanced search page!
Search Now!